**Table S1.** Multivariable Cox proportional hazard regression analysis of PFS when including the interaction term of primary cancer site and the drug score

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | Cutoff | Multivariable | |
| HR (95% CI) | *P* |
| ECOG PS | ≤1 | Reference | < 0.0001\* |
|  | ≥2 | 2.50 (1.62 to 3.87) |  |
| Primary cancer site | BUC only | Reference | 0.48 |
|  | UTUC or both | 0.88 (0.63 to 1.25) |  |
| Bone metastasis | No | Reference | 0.0061\* |
|  | Yes | 1.67 (1.16 to 2.42) |  |
| Liver metastasis | No | Reference | 0.0123\* |
|  | Yes | 1.62 (1.11 to 2.37) |  |
| Drug score | Good (0) | Reference | 0.0009\* |
|  | Intermediate (1–2) | 1.11 (0.81 to 1.53) |  |
|  | Poor (3–4) | 2.37 (1.50 to 3.75) |  |
| Primary cancer site \* Drug score | – | – | 0.0080\* |

BUC, bladder urothelial carcinoma; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; PFS, progression-free survival; UTUC, upper tract urothelial carcinoma

\*Statistically significant